<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00582088</url>
  </required_header>
  <id_info>
    <org_study_id>A-14350</org_study_id>
    <secondary_id>FY06-27</secondary_id>
    <nct_id>NCT00582088</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83</brief_title>
  <acronym>VEE C-84</acronym>
  <official_title>A Phase 2 Open-Label, Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205 When Used as a Booster After TC-83 Primary Immunization in Healthy Adults At-Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the safety and immunogenicity of Venezuelan Equine&#xD;
      Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI GSD 205, as a booster vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      To assess safety of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84,&#xD;
      TSI GSD 205, as a booster vaccination as a single dose or a three-dose series, and To assess&#xD;
      immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI&#xD;
      GSD 205, as a booster vaccination as a single dose or a three-dose series&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      To assess incidence of VEE infection in C-84 boosted personnel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2008</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Adverse Events (ITT)</measure>
    <time_frame>Day 28 after each booster dose</time_frame>
    <description>Frequency of the following adverse events will be evaluated for all intent-to-treat subjects: headache, myalgia, fever, fatigue, sore throat, erythema, tenderness, and warmth.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: TC-83 with PRNT80 ≥ 1:20</measure>
    <time_frame>Between Days 28 and 35 after each booster dose</time_frame>
    <description>Number of initial responders to TC-83 with PRNT80 ≥ 1:20 after C-84 booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: TC-83 with PRNT80 ≥ 1:20</measure>
    <time_frame>12-15 months after booster dose</time_frame>
    <description>Number of initial responders to TC-83 with PRNT80 ≥ 1:20 after C-84 booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: TC-83 with PRNT80 &lt; 1:20</measure>
    <time_frame>Between Days 28 and 35 after each booster dose</time_frame>
    <description>Number of initial responders to TC-83 who are non-responders (PRNT80 &lt; 1:20) to C-84 booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: TC-83 with PRNT80 &lt; 1:20</measure>
    <time_frame>12-15 months after vaccination</time_frame>
    <description>Number of initial responders to TC-83 who are non-responders (PRNT80 &lt; 1:20) to C-84 booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: TC-83 with PRNT80 ≥ 1:20 after three booster doses</measure>
    <time_frame>After three booster doses</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: TC-83 with PRNT80 ≥ 1:20 12- 15 months after first booster dose</measure>
    <time_frame>12- 15 months after first booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: PRNT80 ≥ 1:20 after 1 dose</measure>
    <time_frame>After 1 dose</time_frame>
    <description>Number of rollovers from past C-84 booster study with PRNT80&#xD;
≥ 1:20 after 1 dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: PRNT80 ≥ 1:20 12-15 months post dose for new C-84 Protocol.</measure>
    <time_frame>12-15 months post dose for new C-84 Protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VEE disease among vaccinated subjects who achieved a PRNT80 ≥ 1:20.</measure>
    <time_frame>Length of the study</time_frame>
    <description>The number of confirmed cases of VEE disease among vaccinated subjects who achieved a PRNT80&#xD;
≥ 1:20.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Venezuelan Equine Encephalomyelitis</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VEE C-84</intervention_name>
    <description>Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer &lt;1:20.</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years old.&#xD;
&#xD;
          -  VEE PRNT80 &lt; 1:20 before immunization.&#xD;
&#xD;
          -  (females) Negative urine pregnancy test on the same day before vaccination. Not&#xD;
             planning pregnancy for 3 months.&#xD;
&#xD;
          -  Actively enrolled in the SIP.&#xD;
&#xD;
          -  At risk for exposure to virulent VEE virus (with up-to-date risk assessment).&#xD;
&#xD;
          -  Previous TC-83 vaccination&#xD;
&#xD;
          -  Up-to-date (within 1 year) physical examination/tests.&#xD;
&#xD;
          -  Sign and date the approved informed consent.&#xD;
&#xD;
          -  Willing to return for all follow-up visits.&#xD;
&#xD;
          -  Agree to report adverse event (AE) up to 28 days after vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Over age of 65 years&#xD;
&#xD;
          -  Clinically significant abnormal lab results including evidence of Hepatitis C,&#xD;
             Hepatitis B carrier state, or elevated liver function tests.&#xD;
&#xD;
          -  History of immunodeficiency or current treatment with immunosuppressive medication.&#xD;
&#xD;
          -  (females) Currently breastfeeding.&#xD;
&#xD;
          -  Confirmed human immunodeficiency virus (HIV) titer.&#xD;
&#xD;
          -  Any known allergies to components of the vaccine.&#xD;
&#xD;
          -  A medical condition that in the judgment of the Principal Investigator (PI) would&#xD;
             impact subject safety (i.e-vaccination and or exposure to another alphavirus).&#xD;
&#xD;
          -  Administration of any vaccine within 28 days of C-84.&#xD;
&#xD;
          -  Any unresolved AEs resulting from a previous immunization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Cardile, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>USAMRIID Medical Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.S. Army Medical Research Institute of Infectious Diseases</name>
      <address>
        <city>Fort Deterick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Encephalitis, Viral Infections, Neurologic diseases, Alphavirus Infections, VEE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Encephalomyelitis, Venezuelan Equine</mesh_term>
    <mesh_term>Encephalomyelitis, Equine</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

